Welcome to LookChem.com Sign In|Join Free
  • or
(S)-3-(4-((4'-(Trifluoromethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)hex-4-ynoic acid is a complex organic compound with a unique molecular structure. It is characterized by a hex-4-ynoic acid backbone, which is substituted with a phenyl ring at the 3-position. This phenyl ring is further substituted with a methoxy group, which is connected to a trifluoromethyl-biphenyl moiety. The presence of the trifluoromethyl group and the biphenyl structure contribute to the compound's unique properties and potential applications.

865231-46-5

Post Buying Request

865231-46-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

865231-46-5 Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-(4-((4'-(Trifluoromethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)hex-4-ynoic acid is used as a potent GPR40 agonist for the treatment of metabolic and inflammatory diseases. GPR40 is a polyunsaturated fatty acid receptor that plays a crucial role in regulating various systemic effects. By activating GPR40, (S)-3-(4-((4'-(Trifluoromethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)hex-4-ynoic acid can potentially improve insulin secretion, glucose tolerance, and lipid metabolism, making it a promising candidate for the treatment of obesity and related metabolic disorders.
Additionally, GPR40 has been implicated as a target for treating inflammatory diseases, suggesting that (S)-3-(4-((4'-(Trifluoromethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)hex-4-ynoic acid may also have potential applications in the treatment of inflammatory conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 865231-46-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,5,2,3 and 1 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 865231-46:
(8*8)+(7*6)+(6*5)+(5*2)+(4*3)+(3*1)+(2*4)+(1*6)=175
175 % 10 = 5
So 865231-46-5 is a valid CAS Registry Number.

865231-46-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name (3S)-3-[4-[[3-[4-(trifluoromethyl)phenyl]phenyl]methoxy]phenyl]hex-4-ynoic acid

1.2 Other means of identification

Product number -
Other names AMG-837

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:865231-46-5 SDS

865231-46-5Downstream Products

865231-46-5Relevant academic research and scientific papers

Synthetic method of AMG837 and chiral gamma-methyl benzene pentanol

-

Paragraph 0027; 0029; 0039-0040, (2021/01/29)

The invention discloses a synthetic method of AMG837 and chiral gamma methyl benzene pentanol, and the method comprises the following steps: by using racemic propargyl carbonate and a methane triformate compound as initial raw materials, using bis-(1, 5-c

Method for synthesizing AMG837

-

, (2020/01/03)

The invention relates to a method for synthesizing a compound, in particular to a method for synthesizing AMG837. The method comprises the following steps: a step of preparing an intermediate D by a reaction of an intermediate E with propyne; a step of de

Asymmetric synthesis of chiral β-alkynyl carbonyl and sulfonyl derivatives: Via sequential palladium and copper catalysis

Trost, Barry M.,Masters, James T.,Taft, Benjamin R.,Lumb, Jean-Philip

, p. 6217 - 6231 (2016/08/31)

We present a full account detailing the development of a sequential catalysis strategy for the synthesis of chiral β-alkynyl carbonyl and sulfonyl derivatives. A palladium-catalyzed cross coupling of terminal alkyne donors with acetylenic ester, ketone, a

Discovery of the imidazole-derived GPR40 agonist AM-3189

Ma, Zhihua,Lin, Daniel C.-H.,Sharma, Rajiv,Liu, Jinqian,Zhu, Liusheng,Li, An-Rong,Kohn, Todd,Wang, Yingcai,Liu, Jiwen,Bartberger, Michael D.,Medina, Julio C.,Zhuang, Run,Li, Frank,Zhang, Jane,Luo, Jian,Wong, Simon,Tonn, George R.,Houze, Jonathan B.

, p. 15 - 20 (2015/12/18)

As a follow-up to the GPR40 agonist AMG 837, which was evaluated in clinical trials for the treatment of type II diabetes, further optimization led to the discovery of AM-3189 (13k). AM-3189 is representative of a new class of compounds with minimal CNS penetration, superior pharmacokinetic properties and in vivo efficacy comparable to AMG 837.

Iridium-catalyzed enantioselective allylic alkynylation

Hamilton, James Y.,Sarlah, David,Carreira, Erick M.

supporting information, p. 7532 - 7535 (2013/07/26)

No leaving group needed: With an Ir(P,olefin) complex as catalyst, the direct enantioselective allylic alkynylation of secondary allylic alcohols with potassium alkynyltrifluoroborates as alkynylating reagents has been achieved. High levels of enantiosele

AMG 837: A potent, orally bioavailable GPR40 agonist

Houze, Jonathan B.,Zhu, Liusheng,Sun, Ying,Akerman, Michelle,Qiu, Wei,Zhang, Alex J.,Sharma, Rajiv,Schmitt, Michael,Wang, Yingcai,Liu, Jiwen,Liu, Jinqian,Medina, Julio C.,Reagan, Jeff D.,Luo, Jian,Tonn, George,Zhang, Jane,Lu, Jenny Ying-Lin,Chen, Michael,Lopez, Edwin,Nguyen, Kathy,Yang, Li,Tang, Liang,Tian, Hui,Shuttleworth, Steven J.,Lin, Daniel C.-H.

supporting information; experimental part, p. 1267 - 1270 (2012/03/26)

The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of β-substituted p

Cooperative activation of alkyne and thioamide functionalities; Direct catalytic asymmetric conjugate addition of terminal alkynes to α,β-unsaturated thioamides

Yazaki, Ryo,Kumagai, Naoya,Shibasaki, Masakatsu

, p. 1778 - 1790 (2012/02/02)

A detailed study of the direct catalytic asymmetric conjugate addition of terminal alkynes to α,β-unsaturated thioamides is described. A soft Lewis acid/hard Bronsted base cooperative catalyst, comprising [Cu(CH3CN)4]PF6,

Development of a scalable synthesis of a GPR40 receptor agonist

Walker, Shawn D.,Borths, Christopher J.,Divirgilio, Evan,Huang, Liang,Liu, Pingli,Morrison, Henry,Sugi, Kiyoshi,Tanaka, Masahide,Woo, Jacqueline C. S.,Faul, Margaret M.

, p. 570 - 580 (2011/12/04)

Early process development and salt selection for AMG 837, a novel GPR40 receptor agonist, is described. The synthetic route to AMG 837 involved the convergent synthesis and coupling of two key fragments, (S)-3-(4-hydroxyphenyl) hex-4-ynoic acid (1) and 3-

Enantioselective synthesis of a GPR40 agonist AMG 837 via catalytic asymmetric conjugate addition of terminal alkyne to α,β-unsaturated thioamide

Yazaki, Ryo,Kumagai, Naoya,Shibasaki, Masakatsu

, p. 952 - 955 (2011/04/25)

A concise enantioselective synthetic route to a potent GPR40 agonist AMG 837 is described. The crucial catalytic asymmetric conjugate addition of terminal alkyne was promoted by a soft Lewis acid/hard Bronsted base cooperative catalyst, allowing efficient

Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders

-

Page/Page column 28, (2010/02/15)

The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula [in-line-formulae]Q-L1-P-L2-M-X-L3-A [/in-line-formulae] wherein the definitions of

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 865231-46-5